scholarly journals DEBUNKING THE JULY EFFECT IN TRANSCATHETER INTERVENTIONS IN STRUCTURAL HEART DISEASE: MYTH OR TRUTH? IMPLICATIONS ON RESIDENT CLINICAL TRAINING IN THE CURRENT ERA

2020 ◽  
Vol 75 (11) ◽  
pp. 3485
Author(s):  
Sameer Hirji ◽  
Supreet Singh ◽  
Alexis Okoh ◽  
Alexandra Malarczyk ◽  
Edward Percy ◽  
...  
Keyword(s):  
Heart Disease ◽  
Clinical Training ◽  
Structural Heart Disease ◽  
July Effect ◽  
Transcatheter Interventions

Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease

Circulation ◽  
2021 ◽  
Vol 144 (16) ◽  
pp. 1323-1343
Author(s):  
Paolo Calabrò ◽  
Felice Gragnano ◽  
Giampaolo Niccoli ◽  
Rossella Marcucci ◽  
Marco Zimarino ◽  
...  
Keyword(s):  
Heart Disease ◽  
Antithrombotic Therapy ◽  
Structural Heart Disease ◽  
Current Evidence ◽  
Bleeding Complications ◽  
Tricuspid Valve Repair ◽  
Left Atrial Appendage Occlusion ◽  
Increased Risk ◽  
Valve Implantation ◽  
Transcatheter Interventions

Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.

Computed tomography for cardiac morphology, function, and valve disease

ESC CardioMed ◽  
2018 ◽  
pp. 560-565
Author(s):  
Victoria Delgado
Keyword(s):  
Computed Tomography ◽  
Heart Disease ◽  
Valvular Heart Disease ◽  
Imaging Technique ◽  
Three Dimensional ◽  
Structural Heart Disease ◽  
Patient Specific ◽  
Cardiac Morphology ◽  
Imaging Tool ◽  
Transcatheter Interventions

Computed tomography (CT) has become an important imaging tool to evaluate cardiac anatomy. This three-dimensional, isotropic imaging technique provides volumetric datasets with submillimetre tissue resolution that can be post-processed to define the cardiac structures. CT has become the mainstay imaging technique for selection of patients for, and planning of, transcatheter interventions for structural heart disease. Electrocardiographic-gated CT permits acquisition of cardiac datasets along the cardiac cycle enabling assessment of left and right ventricular function and valvular heart disease. In addition, the advent of three-dimensional printing technologies, which use three-dimensional patient-specific models frequently obtained from CT datasets, has opened a myriad of possibilities in terms of development of anatomical teaching tools, functional models to assess vessel and valve function, planning surgical or transcatheter interventions, and designing of transcatheter cardiac devices. This chapter reviews the role of CT in assessing cardiac morphology and function and valvular heart disease.

scholarly journals Feasibility of multiplane microtransoesophageal echocardiographic guidance in structural heart disease transcatheter interventions in adults

2017 ◽  
Vol 25 (12) ◽  
pp. 669-674 ◽  
Author(s):  
V. J. Nijenhuis ◽  
A. Alipour ◽  
N. C. Wunderlich ◽  
B. J. W. M. Rensing ◽  
G. Gijsbers ◽  
...  
Keyword(s):  
Heart Disease ◽  
Structural Heart Disease ◽  
Transcatheter Interventions

Identification of High-risk Patients for Implantable Cardioverter–Defibrillator Therapy in Asia

2011 ◽  
Vol 3 (1) ◽  
pp. 77
Author(s):  
Cyril YK Ko ◽  
Jeffrey WH Fung ◽  
◽  
Keyword(s):  
Heart Disease ◽  
Implantable Cardioverter Defibrillator ◽  
Asian Population ◽  
Structural Heart Disease ◽  
Medical Problem ◽  
Western World ◽  
Asian Countries ◽  
Cardioverter Defibrillator ◽  
Asian Patients ◽  
Risk Patients

Sudden cardiac death (SCD) is a serious medical problem worldwide. Multiple landmark studies have demonstrated the benefit of implantable cardioverter–defibrillator (ICD) therapy in preventing SCD in at-risk patients. Although the data available in Asia are limited, the disease pattern seems to be different from that in the western world. The Asian population seems to have a lower incidence of SCD. Coronary heart disease, which is the major underlying cause of SCD in the west, may play a less important role in Asian countries. In addition, non-structural heart disease seems to be a more prevalent cause of SCD in Asia. It is thus questionable whether the results of ICD trials can be applied directly to Asian countries, as most of these trials seldom recruited Asian patients. This article will review SCD in Asia, focusing on the epidemiology and risk factors for SCD in Asia and highlighting some unique features that may be different from those seen in the western world.

Sign in / Sign up

Export Citation Format

Share Document